Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barnes, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barnes, P. J.
Related Content
Right arrow Translating Basic Research into Clinical Practice
(Chest. 2006;129:151-155.)
© 2006 American College of Chest Physicians

Reduced Histone Deacetylase in COPD*

Clinical Implications

Peter J. Barnes, DM, DSc

* From the National Heart and Lung Institute, Imperial College, London, UK.

Correspondence to: Peter J. Barnes, DM, DSc, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse St, London SW3 6LY, UK; e-mail: p.j.barnes{at}imperial.ac.uk

Abstract

COPD is characterized by progressive inflammation in the small airways and lung parenchyma, and this is mediated by the increased expression of multiple inflammatory genes. The increased expression of inflammatory genes is regulated by acetylation of core histones around which DNA is wound, and conversely these activated genes are switched off by deacetylation of these histones. Histone deacetylases (HDACs) suppress inflammatory gene expression, but their activity and expression (particularly of HDAC-2) is reduced in the peripheral lung and in alveolar macrophages of patients with COPD. This results in amplification of the inflammatory response as COPD progresses but also accounts for corticosteroid resistance in COPD, since HDAC-2 is required by corticosteroids to switch off activated inflammatory genes. The reduction in HDAC-2 appears to be secondary to the increased oxidative and nitrative stress in COPD lungs. Antioxidants and inhibitors of nitric oxide synthesis may therefore restore corticosteroid sensitivity in COPD, but this can also be achieved by low doses of theophylline, which is an HDAC activator. This mechanism is also relevant to asthmatic patients who smoke, patients with severe asthma and cystic fibrosis, in whom oxidative stress is also increased.

Key Words: asthma • COPD • cystic fibrosis • histone deacetylase




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
R. Chaudhuri, E. Livingston, A. D. McMahon, J. Lafferty, I. Fraser, M. Spears, C. P. McSharry, and N. C. Thomson
Effects of Smoking Cessation on Lung Function and Airway Inflammation in Smokers with Asthma
Am. J. Respir. Crit. Care Med., July 15, 2006; 174(2): 127 - 133.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
R. S. Irwin
The New "Face" of CHEST Heralds a New Era
Chest, January 1, 2006; 129(1): 1 - 3.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Chest Physicians.